Search results
Results from the WOW.Com Content Network
Isomyosamine, also known as MyMD-1 or MYMD-1, is a synthetic derivative of tobacco plant alkaloids being developed as a metabolic- and immunomodulator by MyMD Pharmaceuticals. To date, isomyosamine has been shown to suppress the production of IFN-γ , IL-2 , IL-10 , and TNF-α , and decrease the severity of experimental thyroiditis in a murine ...
Expert Opinion on Therapeutic Patents is a monthly peer-reviewed medical journal covering pharmaceutical patent information across all therapy areas. Each review includes an "expert opinion" section, in which authors provide their personal view on the current status and future direction of the research discussed.
This patent-regime has the potential to limit access to life-saving vaccines and cures, especially for those in poor countries. [32] Pharmaceutical industry executives diminished the idea of sharing intellectual property, arguing that companies would have no incentive to innovate if their patents were considered worthless during a pandemic.
In response to these criticisms, one review concluded that less than 5 percent of medicines on the World Health Organization's list of essential drugs are under patent. [36] Also, the pharmaceutical industry has contributed US$2 billion for healthcare in developing countries, providing HIV/AIDS drugs at lower cost or even free of charge in ...
As with all utility patents in the United States, a biological patent provides the patent holder with the right to exclude others from making, using, selling, or importing the claimed invention or discovery in biology for a limited period of time - for patents filed after 1998, 20 years from the filing date.
E. W. Kemble's "Death's Laboratory" on the cover of Collier's (June 3, 1905). A patent medicine, also known as a proprietary medicine or a nostrum (from the Latin nostrum remedium, or "our remedy") is a commercial product advertised to consumers as an over-the-counter medicine, generally for a variety of ailments, without regard to its actual effectiveness or the potential for harmful side ...
This provides market exclusivity for the drug innovator outside of any patent rights. [5] Second, the Act allows the life of patents covering a drug to be extended by a portion of the time the drug is under regulatory review by the FDA, ensuring that regulatory review will not unduly consume patent life. [5]
A dispute over patents for similar chemical processes. Perfect Web Technologies, Inc. v. InfoUSA, Inc. - CAFC, 2009. Applied KSR-style obviousness analysis to invalidate a patent. Abbott v. Sandoz - Pharmaceutical patent case involving differentiation of products by process.